The main purpose of USP General Chapter 800 is to protect healthcare workers, patients, and the environment from harmful exposure to hazardous drugs. It establishes uniform, enforceable standards for how these drugs are received, stored, compounded, administered, and disposed of across all healthcare settings. Before USP 800, guidance on handling hazardous drugs varied widely. This chapter created a single set of requirements designed to minimize risk at every stage of the process.
What Makes a Drug “Hazardous”
USP 800 builds on work done by the National Institute for Occupational Safety and Health (NIOSH), which maintains a regularly updated list of drugs considered hazardous. A drug qualifies as hazardous if it causes cancer, damages DNA, harms reproductive health, causes developmental problems, or is toxic to organs at low doses. New drugs whose chemical structure and toxicity profile resemble existing hazardous drugs also qualify. Many common medications fall on this list, not just chemotherapy agents. Some hormones, antiviral drugs, and other therapies carry hazardous classifications that require the same careful handling.
Healthcare facilities are expected to cross-reference the NIOSH list and maintain their own internal list of hazardous drugs they handle. That list drives every decision about protective equipment, room design, and cleaning protocols throughout the facility.
Who USP 800 Applies To
The chapter applies to every person and setting where hazardous drugs are handled, which is broader than many people expect. It covers pharmacies, hospitals, clinics, veterinary practices, and any other facility where staff receive shipments of hazardous drugs, compound them into preparations, or administer them to patients. Nurses giving chemotherapy infusions, pharmacy technicians mixing hazardous compounds, and warehouse staff unpacking shipments are all covered. The standard recognizes that exposure risk exists at every touchpoint, not just during compounding.
The Designated Person
Every facility must assign a “designated person” who oversees compliance with USP 800. This individual is responsible for developing and implementing handling procedures, ensuring all personnel are properly trained, and monitoring environmental controls in storage and compounding areas. They must review standard operating procedures at least every 12 months and document that review.
If environmental testing turns up any measurable contamination, the designated person must identify the source, document it, and contain it. Even something as routine as a damaged shipping carton must be treated as a potential spill, reported to the designated person, and managed according to the facility’s written procedures. The role carries real accountability: this person needs to thoroughly understand the risks of noncompliance and has a duty to report hazardous situations to management.
Engineering Controls and Room Requirements
USP 800 requires specific physical infrastructure to contain hazardous drug particles and vapors. The two key concepts are containment primary engineering controls (C-PECs) and containment secondary engineering controls (C-SECs).
C-PECs are the devices where actual compounding takes place, such as biological safety cabinets and compounding aseptic containment isolators. These units are designed to capture airborne drug particles before they reach the worker. A compounding aseptic containment isolator must achieve a minimum of 15 air changes per hour and maintain consistent negative pressure inside the chamber.
The room housing these devices matters too. A biological safety cabinet or containment isolator used for sterile compounding must sit inside a cleanroom-grade area that is physically separated from surrounding spaces, with at least 12 air changes per hour and negative pressure relative to adjacent rooms. That negative pressure prevents contaminated air from drifting into cleaner areas. USP 800 does allow a less stringent setup for low- and medium-risk nonsterile hazardous drug compounding, but the tradeoff is a much shorter expiration window on the finished product: no more than 12 hours.
Personal Protective Equipment
Protective equipment requirements scale with the level of exposure risk. At a minimum, anyone handling hazardous drugs needs chemotherapy-tested gloves. For compounding, the requirements expand to include protective gowns, double gloving, eye and face protection, and in some cases respiratory protection. Standard latex exam gloves are not sufficient; gloves must be specifically tested against chemotherapy drug permeation.
The chapter applies these requirements not just to compounding but also to receiving, unpacking, storing, and administering hazardous drugs. A nurse administering an oral hazardous drug and a technician unpacking a shipment both need appropriate protective equipment, though the specific items differ based on the task and the drug’s form.
Cleaning: A Three- or Four-Step Process
USP 800 distinguishes between routine cleaning and the specialized process required for surfaces that contact hazardous drugs. For nonsterile work areas, three steps are required: deactivation (chemically neutralizing drug residue), decontamination (removing residue from the surface), and cleaning (removing organic and inorganic material). Sterile compounding areas add a fourth step: disinfection.
This layered approach reflects the fact that hazardous drug residue can persist on surfaces long after a spill or routine compounding session. Simply wiping down a counter with a standard cleaner is not enough to eliminate exposure risk.
Environmental Monitoring
Facilities must perform surface wipe sampling at least every six months to check for hazardous drug contamination. Sampling locations include any surface where hazardous drugs might be present: workbenches, storage shelves, secondary containment units, and the interior of compounding equipment. If a facility changes the drugs it handles, modifies its procedures, or installs new equipment, additional sampling is required outside the regular schedule.
Wipe sampling serves as an objective check on whether engineering controls, cleaning protocols, and work practices are actually working. Detectable contamination triggers investigation and corrective action by the designated person.
Assessment of Risk
USP 800 includes a provision called the Assessment of Risk, which allows facilities to use professional judgment when handling certain dosage forms that pose lower exposure risk. For example, administering an intact tablet of a hazardous drug involves far less exposure potential than compounding a powder into a solution. The Assessment of Risk must be documented and must consider the specific drug, its dosage form, and the handling activity involved. It does not exempt a facility from USP 800 entirely. It allows tailored precautions for situations where the full suite of controls would be disproportionate to the actual risk.
This flexibility is important because the NIOSH hazardous drug list includes hundreds of medications, many of which are handled in forms that pose minimal aerosolization or skin contact risk. Without the Assessment of Risk provision, facilities would face impractical compliance burdens for routine tasks like handing a patient a sealed bottle of pills.